rhein has been researched along with Neoplasms in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (53.85) | 24.3611 |
| 2020's | 6 (46.15) | 2.80 |
| Authors | Studies |
|---|---|
| Gao, P; Hao, X; Liu, X; Xu, H; Zhan, P; Zou, J | 1 |
| Huang, SY; Hung, CC; Kao, MC; Kuo, CY; Lee, TE; Teng, YN; Wu, TS | 1 |
| Adabbo, G; Botta, B; Cammarone, S; Conenna, M; Di Marcotullio, L; Ghirga, F; Infante, P; Lamelza, L; Mori, M; Pisano, L; Quaglio, D | 1 |
| Chu, K; Han, L; Li, T; Ouyang, H; Qiu, L; Wang, X; Xu, W; Zhang, X | 1 |
| Jin, Q; Ni, Y; Zhang, D; Zhang, J | 1 |
| Ahn, KS; Baek, SH; Banik, K; Harsha, C; Henamayee, S; Kunnumakkara, AB; Sailo, BL; Shabnam, B; Srilakshmi, S; Vgm, N | 1 |
| Chen, J; Jiang, Y; Lei, G; Liu, M; Liu, S; Pei, R | 1 |
| Feng, H; Fu, Z; Li, D; Zhu, Y | 1 |
| Hua, H; Jiang, Y; Kong, Q; Liu, S; Luo, T; Shao, T; Song, P; Wang, J | 1 |
| Chu, K; Guo, Y; Han, L; Li, T; Ouyang, H; Qiu, L; Wang, X; Xu, W | 1 |
| Calin, M; Coroaba, A; Doroftei, F; Durdureanu-Angheluta, A; Maier, SS; Minea, B; Pinteala, M; Simionescu, BC; Simionescu, M; Uritu, CM | 1 |
| Bian, Y; Cao, H; Dong, S; Li, J; Liu, P; Sun, L; Sun, M; Sun, R; Wu, C; Xue, J; Zhou, H | 1 |
| Sun, G; Wang, B; Yang, C; Yang, X | 1 |
5 review(s) available for rhein and Neoplasms
| Article | Year |
|---|---|
Recent progress in the structural modification and pharmacological activities of ligustrazine derivatives.
Topics: Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Bacteria; Cardiovascular Diseases; Humans; Inflammation; Molecular Structure; Neoplasms; Neuroprotective Agents; Pyrazines | 2018 |
Discovery of necrosis avidity of rhein and its applications in necrosis imaging.
Topics: Anthraquinones; Diagnostic Imaging; Myocardial Infarction; Necrosis; Neoplasms | 2020 |
Therapeutic Emergence of Rhein as a Potential Anticancer Drug: A Review of Its Molecular Targets and Anticancer Properties.
Topics: Anthraquinones; Antineoplastic Agents, Phytogenic; Fallopia multiflora; Female; Humans; Male; Neoplasms; Plant Roots; Rheum | 2020 |
Rhein Derivatives, A Promising Pivot?
Topics: Animals; Anthraquinones; Arthritis; Cell Line, Tumor; Chemistry, Pharmaceutical; Diabetic Nephropathies; Drug Design; Humans; Inflammation; Inhibitory Concentration 50; Neoplasms | 2021 |
Research Progress on the Antitumor Effects of Rhein: Literature Review.
Topics: Anthraquinones; Antineoplastic Agents; Apoptosis; Cell Proliferation; Humans; Lipid Metabolism; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasms; Neovascularization, Pathologic; Phosphorylation | 2017 |
8 other study(ies) available for rhein and Neoplasms
| Article | Year |
|---|---|
Novel application of rhein and its prodrug diacerein for reversing cancer-related multidrug resistance through the dual inhibition of P-glycoprotein efflux and STAT3-mediated P-glycoprotein expression.
Topics: Anthraquinones; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Neoplasms; Prodrugs; STAT3 Transcription Factor | 2022 |
Exploring the Potential of Anthraquinone-Based Hybrids for Identifying a Novel Generation of Antagonists for the Smoothened Receptor in HH-Dependent Tumour.
Topics: Anthraquinones; Antineoplastic Agents; Hedgehog Proteins; Humans; Neoplasms; Receptors, G-Protein-Coupled; Smoothened Receptor | 2023 |
Evaluation of intestinal permeation enhancement with carboxymethyl chitosan-rhein polymeric micelles for oral delivery of paclitaxel.
Topics: Administration, Oral; Animals; Anthraquinones; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; Caco-2 Cells; Chitosan; Disease Models, Animal; Drug Carriers; Drug Compounding; Humans; Intestinal Mucosa; Male; Mice; Micelles; Neoplasms; Paclitaxel; Permeability; Rats; Tissue Distribution; Verapamil | 2020 |
Preparation, characterization, and in vivo study of rhein solid lipid nanoparticles for oral delivery.
Topics: Administration, Oral; Animals; Anthraquinones; Antineoplastic Agents; Biological Availability; Cell Line, Tumor; Cell Survival; Drug Carriers; Laxatives; Lipids; Male; Nanoparticles; Neoplasms; Particle Size; Rabbits; Solubility | 2017 |
The natural agent rhein induces β-catenin degradation and tumour growth arrest.
Topics: Animals; Anthraquinones; Antineoplastic Agents; beta Catenin; Biological Products; Cell Cycle Checkpoints; Cell Proliferation; Female; Glycogen Synthase Kinase 3 beta; HeLa Cells; Hep G2 Cells; Humans; Mice, Inbred BALB C; Mice, Nude; Neoplasm Proteins; Neoplasms; Proteasome Endopeptidase Complex; Proteolysis; Proto-Oncogene Proteins c-akt; RNA, Messenger; S Phase; Xenograft Model Antitumor Assays | 2018 |
Preparation and evaluation of carboxymethyl chitosan-rhein polymeric micelles with synergistic antitumor effect for oral delivery of paclitaxel.
Topics: Administration, Oral; Animals; Anthraquinones; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Chitosan; Drug Carriers; Drug Liberation; Drug Synergism; Humans; Male; Mice, Inbred ICR; Micelles; Neoplasms; Paclitaxel; Verapamil | 2019 |
Heparin-anthranoid conjugates associated with nanomagnetite particles and their cytotoxic effect on cancer cells.
Topics: Anthraquinones; Cell Survival; Drug Carriers; Drug Delivery Systems; Drug Evaluation, Preclinical; Hep G2 Cells; Heparin; Humans; Magnetics; Magnetite Nanoparticles; Nanoconjugates; Neoplasms | 2014 |
Novel rhein analogues as potential anticancer agents.
Topics: Anthraquinones; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Humans; Neoplasms; Structure-Activity Relationship | 2011 |